SE168308C1 - - Google Patents

Info

Publication number
SE168308C1
SE168308C1 SE168308DA SE168308C1 SE 168308 C1 SE168308 C1 SE 168308C1 SE 168308D A SE168308D A SE 168308DA SE 168308 C1 SE168308 C1 SE 168308C1
Authority
SE
Sweden
Application number
Publication of SE168308C1 publication Critical patent/SE168308C1/xx

Links

SE168308D SE168308C1 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE168308T

Publications (1)

Publication Number Publication Date
SE168308C1 true SE168308C1 (xx)

Family

ID=41958801

Family Applications (1)

Application Number Title Priority Date Filing Date
SE168308D SE168308C1 (xx)

Country Status (1)

Country Link
SE (1) SE168308C1 (xx)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016135263A1 (en) 2015-02-27 2016-09-01 Armin Scherhag No donors for the treatment of stress-induced pulmonary haemorrhage in animals
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016135263A1 (en) 2015-02-27 2016-09-01 Armin Scherhag No donors for the treatment of stress-induced pulmonary haemorrhage in animals
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
CN1681495B (zh) 用于治疗过度增生性疾病的组合物
AU2020209215B2 (en) PCSK9 inhibitors and methods of use thereof
EP2392567B1 (en) Benzothiazine derivatives and their use as lxr modulators
EP1951673B1 (en) Heterocyclic cetp inhibitors
CA2909442A1 (en) N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CA2907071A1 (en) Substituted amide compounds
CA2881726A1 (en) Extended release compositions of an aminoalkyl nitrate
EP2094643B1 (en) N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
SE168308C1 (xx)